Those are common side effects for the GLP-1 class of diabetes medicines.

Blackstone and GLP did not immediately respond to Reuters' request for comments.

Blackstone Group is also among other groups interested in GLP, they added.

All responses on GLP-1 were not significantly different from nondiabetic control subjects.

G7 and Singapore-based GLP did not immediately respond to requests for comment.